Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks rebounded in the second quarter, delivering a strong recovery. The Russell Midcap Growth Index (up 18.20%) outperformed the Russell Midcap® Value Index (up 5.34%) in the quarter. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its second-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company. The one-month return of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was 11.69%, and its shares lost 86.53% of their value over the last 52 weeks. On September 02, 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock closed at $18.16 per share, with a market capitalization of $1.901 billion.

Carillon Eagle Mid Cap Growth Fund stated the following regarding Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in its second quarter 2025 investor letter:

"Sarepta Therapeutics, Inc. (NASDAQ:SRPT) develops RNA-targeted medicines and gene therapies for rare neuromuscular diseases. The company reported quarterly revenue that exceeded expectations, but posted a larger than expected loss per share and revised its 2025 sales forecast downward. The stock sold off sharply after a second patient died from acute liver failure after being treated with Elevidys, its gene therapy for patients with Duchenne muscular dystrophy."

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Sarepta Therapeutics, Inc. (NASDAQ:SRPT) at the end of the second quarter, which was 47 in the previous quarter. While we acknowledge the potential of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and shared the list of Jim Cramer talked about. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.